Sisram Medical Ltd (HKG:1696)

Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	349.11	359.29	354.48	294.29	162.1
Revenue Growth (YoY)	-2.83%	1.36%	20.45%	81.56%	-6.58%
Cost of Revenue	132.43	139.77	152.25	127.43	71.79
Gross Profit	216.68	219.53	202.23	166.86	90.3
Selling, General & Admin	165.09	159.44	128.76	100.71	58.96
Research & Development	15.94	18.03	18.02	15.59	10.96
Other Operating Expenses	7.98	4.03	10.04	7.8	3.78
Operating Expenses	189	181.5	156.82	124.1	73.7
Operating Income	27.68	38.03	45.41	42.76	16.6
Interest Expense	-2.46	-2.06	-1.74	-2.01	-1.06
Interest & Investment Income	0.79	0.6	0.61	0.54	0.77
Earnings From Equity Investments	0.03	-0.42	-0.52	-0.31	-
Currency Exchange Gain (Loss)	-	-	-	0.49	-
Other Non Operating Income (Expenses)	2.35	0.99	0.48	0.19	0.01
EBT Excluding Unusual Items	28.39	37.13	44.24	41.67	16.32
Gain (Loss) on Sale of Investments	4.15	-	-	-	-
Other Unusual Items	-	-	-	-	0.34
Pretax Income	32.54	37.13	44.24	41.67	16.66
Income Tax Expense	3.78	4.23	4.16	9.15	1.98
Earnings From Continuing Operations	28.77	32.9	40.08	32.52	14.68
Minority Interest in Earnings	-3.64	-1.4	0.09	-1.28	-1.34
Net Income	25.13	31.5	40.17	31.25	13.34
Net Income to Common	25.13	31.5	40.17	31.25	13.34
Net Income Growth	-20.23%	-21.59%	28.57%	134.15%	-35.80%
Shares Outstanding (Basic)	468	467	466	453	442
Shares Outstanding (Diluted)	468	468	467	453	442
Shares Change (YoY)	-	0.34%	3.07%	2.42%	-
EPS (Basic)	0.05	0.07	0.09	0.07	0.03
EPS (Diluted)	0.05	0.07	0.09	0.07	0.03
EPS Growth	-20.36%	-21.84%	24.78%	128.63%	-35.80%
Free Cash Flow	30.33	35.37	17.29	29.41	16.46
Free Cash Flow Per Share	0.07	0.08	0.04	0.07	0.04
Dividend Per Share	0.016	0.020	0.022	0.020	0.009
Dividend Growth	-19.80%	-8.84%	10.20%	123.02%	-36.07%
Gross Margin	62.07%	61.10%	57.05%	56.70%	55.71%
Operating Margin	7.93%	10.58%	12.81%	14.53%	10.24%
Profit Margin	7.20%	8.77%	11.33%	10.62%	8.23%
Free Cash Flow Margin	8.69%	9.84%	4.88%	9.99%	10.16%
EBITDA	38.91	47.5	53.99	51.58	23.8
EBITDA Margin	11.14%	13.22%	15.23%	17.53%	14.68%
D&A For EBITDA	11.23	9.47	8.59	8.82	7.2
EBIT	27.68	38.03	45.41	42.76	16.6
EBIT Margin	7.93%	10.58%	12.81%	14.53%	10.24%
Effective Tax Rate	11.60%	11.40%	9.41%	21.96%	11.89%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.